A single gene turns colorectal cancer cells back into normal tissue in mice

June 18, 2015, Cell Press
Immunofluorescent images of intestinal organoid cultures. Gene silencing of Apc in intestinal organoids triggered a cancer-like response (left). Reactivation of Apc expression restored normal cell division (right). Credit: Kevin P. O'Rourke

Anti-cancer strategies generally involve killing off tumor cells. However, cancer cells may instead be coaxed to turn back into normal tissue simply by reactivating a single gene, according to a study published June 18th in the journal Cell. Researchers found that restoring normal levels of a human colorectal cancer gene in mice stopped tumor growth and re-established normal intestinal function within only 4 days. Remarkably, tumors were eliminated within 2 weeks, and signs of cancer were prevented months later. The findings provide proof of principle that restoring the function of a single tumor suppressor gene can cause tumor regression and suggest future avenues for developing effective cancer treatments.

Colorectal is the second leading cause of cancer-related death in developed countries, accounting for nearly 700,000 deaths worldwide each year. "Treatment regimes for advanced involve combination chemotherapies that are toxic and largely ineffective, yet have remained the backbone of therapy over the last decade," says senior study author Scott Lowe of the Memorial Sloan Kettering Cancer Center.

Up to 90% of colorectal tumors contain inactivating mutations in a called adenomatous polyposis coli (Apc). Although these mutations are thought to initiate colorectal cancer, it has not been clear whether Apc inactivation also plays a role in tumor growth and survival once cancer has already developed.

"We wanted to know whether correcting the disruption of Apc in established cancers would be enough to stop tumor growth and induce regression," says first author Lukas Dow of Weill Cornell Medical College. This question has been challenging to address experimentally because attempts to restore function to lost or mutated genes in often trigger excess gene activity, causing other problems in normal cells.

To overcome this challenge, Lowe and his team used a genetic technique to precisely and reversibly disrupt Apc activity in a novel mouse model of colorectal cancer. While the vast majority of existing animal models of colorectal cancer develop tumors primarily in the small intestine, the new animal model also developed tumors in the colon, similar to patients. Consistent with previous findings, Apc suppression in the animals activated the Wnt signaling pathway, which is known to control cell proliferation, migration, and survival.

Colorectal cancer cells can revert tofunctioning normal cells in vivo when Apclevels are restored, even if potentoncogenic insults such as Kras and p53mutations are present. Credit: Dow et al./Cell 2015

When Apc was reactivated, Wnt signaling returned to normal levels, stopped proliferating, and intestinal cells recovered normal function. Tumors regressed and disappeared or reintegrated into normal tissue within 2 weeks, and there were no signs of cancer relapse over a 6-month follow-up period. Moreover, this approach was effective in treating mice with malignant colorectal cancer tumors containing Kras and p53 mutations, which are found in about half of colorectal tumors in humans.

Although Apc reactivation is unlikely to be relevant to other types of cancer, the general experimental approach could have broad implications. "The concept of identifying tumor-specific driving mutations is a major focus of many laboratories around the world," Dow says. "If we can define which types of mutations and changes are the critical events driving tumor growth, we will be better equipped to identify the most appropriate treatments for individual cancers."

For their own part, Lowe and his team will next examine the consequences of Apc reactivation in tumors that progress beyond local invasion to produce distant metastases. They will also continue to investigate why Apc is so effective at suppressing colon , with the goal of one day mimicking this effect with drug treatments.

"It is currently impractical to directly restore Apc function in patients with colorectal cancer, and past evidence suggests that completely blocking Wnt signaling would likely be severely toxic to normal intestinal cells," Lowe says. "However, our findings suggest that small molecules aimed at modulating, but not blocking, the Wnt pathway might achieve similar effects to Apc reactivation. Further work will be critical to determine whether WNT inhibition or similar approaches would provide long-term therapeutic value in the clinic."

Explore further: Gut microbes turn carbs into colorectal cancer

More information: Cell, Dow et al.: "Apc restoration promotes cellular differentiation and reestablishes crypt homeostasis in colorectal cancer." dx.doi.org/10.1016/j.cell.2015.05.033

Related Stories

Gut microbes turn carbs into colorectal cancer

July 17, 2014
Colorectal cancer has been linked to carbohydrate-rich western diets, but the underlying mechanisms have been unclear. A study published by Cell Press July 17th in the journal Cell shows that gut microbes metabolize carbohydrates ...

Penn vet team points to new colon cancer culprit

March 16, 2015
Colon cancer is a heavily studied disease—and for good reason. It is one of the leading causes of cancer-related deaths worldwide, and its numbers are on the rise, from 500,00 deaths in 1990 to 700,000 in 2010.

Research offers insight into cellular biology of colorectal cancer

August 21, 2014
A study recently published in the journal Carcinogenesis by researchers at the University of Kansas shows a new role for the protein adenomatous polyposis coli (APC) in suppressing colorectal cancer—the second-leading cause ...

Study identifies a likely key driver of colorectal cancer development and progression

April 14, 2014
A new study identifies a molecule that is a probable driving force in colorectal cancer and suggests that the molecule could be an important target for colorectal cancer treatment and a valuable biomarker of tumor progression.

Researchers trace origins of colorectal cancer tumor cells

February 9, 2015
For the first time, Keck Medicine of the University of Southern California (USC) cancer researchers have traced the origins of colorectal cancer cells, finding important clues to why tumor cells become "good" or "bad," with ...

Recommended for you

Parental 'feeding styles' reflect children's genes

November 20, 2018
New research from King's College London and UCL challenges the idea that a child's weight largely reflects the way their parents feed them. Instead, parents appear to adopt feeding styles in response to their children's natural ...

Scientists identify new genetic causes linked to abnormal pregnancies and miscarriages

November 20, 2018
A team of scientists at the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University have identified three genes responsible for recurrent molar pregnancies, a rare complication that occurs ...

A study suggests that epigenetic treatments could trigger the development of aggressive tumours

November 20, 2018
A study headed by the Institute for Research in Biomedicine (IRB Barcelona) and published in the journal Nature Cell Biology examined whether the opening of chromatin (a complex formed by DNA bound to proteins) is the factor ...

Redefining colorectal cancer subtypes

November 20, 2018
There is a long-standing belief that colorectal cancer (CRC), which causes some 50,000 deaths in the United States each year, can be categorized into distinct molecular subtypes. In a paper published recently in the journal Genome ...

Mutation that causes autism and intellectual disability makes brain less flexible

November 19, 2018
About 1 percent of patients diagnosed with autism spectrum disorder and intellectual disability have a mutation in a gene called SETD5. Scientists have now discovered what happens on a molecular level when the gene is mutated ...

Progress in genetic testing of embryos stokes fears of designer babies

November 16, 2018
Recent announcements by two biotechnology companies have stoked fears that designer babies could soon be an option for those who can afford to pick and choose which features they want for their offspring. The companies, MyOme ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.